A study of Abemaciclib, and CDK 4/6 inhibitor, in combination with Fulvestrant compared to chemotherapy in women with HR positive, HER2 negative advanced breast cancer with visceral metastases (I3Y-MC-JPCU)
A study of Abemaciclib, and CDK 4/6 inhibitor, in combination with Fulvestrant compared to chemotherapy in women with HR positive, HER2 negative advanced breast cancer with visceral metastases (I3Y-MC-JPCU)
Trial Category:
Breast
Contact(s)
Location(s)
Nebraska Cancer Specialists, Omaha, NE
